Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.06
LH's Cash to Debt is ranked lower than
97% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.71 vs. LH: 0.06 )
Ranked among companies with meaningful Cash to Debt only.
LH' s 10-Year Cash to Debt Range
Min: 0.02  Med: 0.07 Max: 0.59
Current: 0.06
0.02
0.59
Equity to Asset 0.32
LH's Equity to Asset is ranked lower than
84% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. LH: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
LH' s 10-Year Equity to Asset Range
Min: 0.14  Med: 0.43 Max: 0.63
Current: 0.32
0.14
0.63
Interest Coverage 8.31
LH's Interest Coverage is ranked lower than
79% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10000.00 vs. LH: 8.31 )
Ranked among companies with meaningful Interest Coverage only.
LH' s 10-Year Interest Coverage Range
Min: 1.03  Med: 11.71 Max: 22.66
Current: 8.31
1.03
22.66
F-Score: 4
Z-Score: 1.86
M-Score: -2.08
WACC vs ROIC
5.68%
7.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.14
LH's Operating margin (%) is ranked higher than
82% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. LH: 13.14 )
Ranked among companies with meaningful Operating margin (%) only.
LH' s 10-Year Operating margin (%) Range
Min: -4.39  Med: 17.23 Max: 19.94
Current: 13.14
-4.39
19.94
Net-margin (%) 6.26
LH's Net-margin (%) is ranked higher than
72% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. LH: 6.26 )
Ranked among companies with meaningful Net-margin (%) only.
LH' s 10-Year Net-margin (%) Range
Min: -9.16  Med: 10.02 Max: 12.02
Current: 6.26
-9.16
12.02
ROE (%) 13.06
LH's ROE (%) is ranked higher than
80% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.85 vs. LH: 13.06 )
Ranked among companies with meaningful ROE (%) only.
LH' s 10-Year ROE (%) Range
Min: -45.84  Med: 19.25 Max: 28.64
Current: 13.06
-45.84
28.64
ROA (%) 4.66
LH's ROA (%) is ranked higher than
72% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. LH: 4.66 )
Ranked among companies with meaningful ROA (%) only.
LH' s 10-Year ROA (%) Range
Min: -8.18  Med: 9.98 Max: 11.43
Current: 4.66
-8.18
11.43
ROC (Joel Greenblatt) (%) 59.11
LH's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. LH: 59.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -31.47  Med: 95.55 Max: 138.05
Current: 59.11
-31.47
138.05
Revenue Growth (3Y)(%) 8.50
LH's Revenue Growth (3Y)(%) is ranked higher than
66% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. LH: 8.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LH' s 10-Year Revenue Growth (3Y)(%) Range
Min: -21.4  Med: 10.20 Max: 20
Current: 8.5
-21.4
20
EBITDA Growth (3Y)(%) 5.50
LH's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. LH: 5.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -8.3  Med: 10.50 Max: 17.6
Current: 5.5
-8.3
17.6
EPS Growth (3Y)(%) 5.00
LH's EPS Growth (3Y)(%) is ranked higher than
54% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. LH: 5.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LH' s 10-Year EPS Growth (3Y)(%) Range
Min: 5  Med: 15.35 Max: 82.8
Current: 5
5
82.8
» LH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

LH Guru Trades in Q2 2014

Louis Moore Bacon 3,935 sh (New)
Tom Gayner 15,000 sh (New)
Paul Tudor Jones 7,020 sh (New)
Ray Dalio 31,466 sh (+291.76%)
John Rogers 1,087,739 sh (+5.85%)
Charles Brandes 154,198 sh (+3.68%)
Wallace Weitz 999,816 sh (+0.21%)
John Hussman 62,900 sh (unchged)
First Pacific Advisors 84,500 sh (unchged)
Mario Gabelli 4,000 sh (unchged)
David Dreman Sold Out
Larry Robbins Sold Out
Jeff Auxier 4,630 sh (-3.14%)
Westport Asset Management 140,000 sh (-6.67%)
Scott Black 79,092 sh (-22.57%)
Richard Pzena 1,654,529 sh (-26.69%)
Chris Davis 6,747,256 sh (-29.99%)
Jeremy Grantham 213,871 sh (-77.86%)
Joel Greenblatt 2,725 sh (-95.40%)
» More
Q3 2014

LH Guru Trades in Q3 2014

Jim Simons 238,200 sh (New)
Joel Greenblatt 317,530 sh (+11552.50%)
Ray Dalio 54,536 sh (+73.32%)
John Rogers 1,389,464 sh (+27.74%)
First Pacific Advisors 99,500 sh (+17.75%)
Charles Brandes 165,695 sh (+7.46%)
Tom Gayner 15,000 sh (unchged)
John Hussman 62,900 sh (unchged)
Jeff Auxier 4,630 sh (unchged)
Westport Asset Management 140,000 sh (unchged)
Mario Gabelli 4,000 sh (unchged)
Louis Moore Bacon Sold Out
Wallace Weitz 988,891 sh (-1.09%)
Richard Pzena 1,558,296 sh (-5.82%)
Chris Davis 5,989,780 sh (-11.23%)
Scott Black 69,949 sh (-11.56%)
Paul Tudor Jones 4,047 sh (-42.35%)
Jeremy Grantham 122,271 sh (-42.83%)
» More
Q4 2014

LH Guru Trades in Q4 2014

Steven Cohen 123,800 sh (New)
Louis Moore Bacon 50,000 sh (New)
Paul Tudor Jones 13,705 sh (+238.65%)
Jim Simons 597,100 sh (+150.67%)
Ray Dalio 70,036 sh (+28.42%)
Scott Black 74,051 sh (+5.86%)
Wallace Weitz 996,606 sh (+0.78%)
Mario Gabelli 4,000 sh (unchged)
Chris Davis 5,928,873 sh (unchged)
Westport Asset Management Sold Out
Tom Gayner Sold Out
John Hussman Sold Out
John Rogers 1,386,680 sh (-0.20%)
Chris Davis 5,928,873 sh (-1.02%)
Jeff Auxier 4,580 sh (-1.08%)
Joel Greenblatt 284,471 sh (-10.41%)
Jeremy Grantham 91,180 sh (-25.43%)
Charles Brandes 117,707 sh (-28.96%)
Richard Pzena 830,648 sh (-46.70%)
First Pacific Advisors 50,400 sh (-49.35%)
» More
Q1 2015

LH Guru Trades in Q1 2015

John Keeley 10,760 sh (New)
John Hussman 90,000 sh (New)
Caxton Associates 3,000 sh (New)
Ray Dalio 96,536 sh (+37.84%)
Mario Gabelli 5,000 sh (+25.00%)
John Rogers 1,404,802 sh (+1.31%)
First Pacific Advisors 50,400 sh (unchged)
Charles Brandes Sold Out
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Scott Black 73,891 sh (-0.22%)
Richard Pzena 728,078 sh (-12.35%)
Paul Tudor Jones 10,793 sh (-21.25%)
Chris Davis 4,443,459 sh (-25.05%)
Wallace Weitz 746,258 sh (-25.12%)
Jeff Auxier 3,380 sh (-26.20%)
Jeremy Grantham 39,680 sh (-56.48%)
Jim Simons 250,605 sh (-58.03%)
Joel Greenblatt 104,024 sh (-63.43%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Laboratory Corp of America Hldgs

John Rogers Comments on Laboratory Corp. of America Holdings - May 07, 2014

We purchased a previous holding in our mid ca p fund, Laboratory Corp. of America Holdings (LH). LabCorp maintains a leading market position in an indust ry that continues to show promising growth potential du e to technological advances, aging demographics, health care cost containment, and preventative medicine. LabCorp maintains a solid balance sheet, generates a significant amount of free cash flow and has been returning value to shareholders through share repurchases. The company operates with an experienced management team that is conservative yet willing to take slight risks in order to grow the business long-term.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Top Ranked Articles about Laboratory Corp of America Hldgs

John Hussman Increases Portfolio in 1Q2015
John Hussman (Trades, Portfolio) is known for his negative thoughts on the Federal Reserve and the U.S. Treasury. He has been named the "Prophet of Doom" because he predicted the financial crisis of 2008 and says there is another to come that will be much worse. Read more...
Westport Buys Apparel Retailer Express During Q4
Andrew J. Knuth founded Westport Asset Management (Trades, Portfolio) in 1983 with a focus on investing in small-cap companies for institutional clients. Read more...
The Top Five Guru-Held Mid-Cap Stocks of Q2
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mid-cap companies which are held by the most gurus. The following five mid-capped companies are held by the largest number of gurus during the past quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.40
LH's P/E(ttm) is ranked higher than
67% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. LH: 26.40 )
Ranked among companies with meaningful P/E(ttm) only.
LH' s 10-Year P/E(ttm) Range
Min: 12.98  Med: 17.20 Max: 27.47
Current: 26.4
12.98
27.47
Forward P/E 14.66
LH's Forward P/E is ranked higher than
78% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.16 vs. LH: 14.66 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.30
LH's PE(NRI) is ranked higher than
68% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. LH: 26.30 )
Ranked among companies with meaningful PE(NRI) only.
LH' s 10-Year PE(NRI) Range
Min: 12.97  Med: 17.20 Max: 27.46
Current: 26.3
12.97
27.46
P/B 2.73
LH's P/B is ranked higher than
59% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. LH: 2.73 )
Ranked among companies with meaningful P/B only.
LH' s 10-Year P/B Range
Min: 2.61  Med: 3.51 Max: 5.41
Current: 2.73
2.61
5.41
P/S 1.68
LH's P/S is ranked higher than
74% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. LH: 1.68 )
Ranked among companies with meaningful P/S only.
LH' s 10-Year P/S Range
Min: 1.33  Med: 1.72 Max: 2.97
Current: 1.68
1.33
2.97
PFCF 31.17
LH's PFCF is ranked lower than
55% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.01 vs. LH: 31.17 )
Ranked among companies with meaningful PFCF only.
LH' s 10-Year PFCF Range
Min: 9.15  Med: 14.64 Max: 32.44
Current: 31.17
9.15
32.44
POCF 20.44
LH's POCF is ranked higher than
54% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.04 vs. LH: 20.44 )
Ranked among companies with meaningful POCF only.
LH' s 10-Year POCF Range
Min: 7.45  Med: 11.39 Max: 21.26
Current: 20.44
7.45
21.26
EV-to-EBIT 21.84
LH's EV-to-EBIT is ranked higher than
52% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.19 vs. LH: 21.84 )
Ranked among companies with meaningful EV-to-EBIT only.
LH' s 10-Year EV-to-EBIT Range
Min: 8.8  Med: 12.00 Max: 22
Current: 21.84
8.8
22
PEG 4.46
LH's PEG is ranked lower than
66% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. LH: 4.46 )
Ranked among companies with meaningful PEG only.
LH' s 10-Year PEG Range
Min: 0.82  Med: 1.47 Max: 5.61
Current: 4.46
0.82
5.61
Shiller P/E 21.79
LH's Shiller P/E is ranked higher than
75% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.25 vs. LH: 21.79 )
Ranked among companies with meaningful Shiller P/E only.
LH' s 10-Year Shiller P/E Range
Min: 16.03  Med: 19.97 Max: 33.21
Current: 21.79
16.03
33.21
Current Ratio 1.65
LH's Current Ratio is ranked lower than
74% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. LH: 1.65 )
Ranked among companies with meaningful Current Ratio only.
LH' s 10-Year Current Ratio Range
Min: 0.47  Med: 1.66 Max: 3.64
Current: 1.65
0.47
3.64
Quick Ratio 1.52
LH's Quick Ratio is ranked lower than
69% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. LH: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
LH' s 10-Year Quick Ratio Range
Min: 0.44  Med: 1.56 Max: 3.45
Current: 1.52
0.44
3.45
Days Inventory 13.10
LH's Days Inventory is ranked higher than
83% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.61 vs. LH: 13.10 )
Ranked among companies with meaningful Days Inventory only.
LH' s 10-Year Days Inventory Range
Min: 9.77  Med: 12.13 Max: 16.03
Current: 13.1
9.77
16.03
Days Sales Outstanding 67.97
LH's Days Sales Outstanding is ranked lower than
52% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. LH: 67.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
LH' s 10-Year Days Sales Outstanding Range
Min: 44.64  Med: 54.57 Max: 110.1
Current: 67.97
44.64
110.1

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.02
LH's Price/Projected FCF is ranked higher than
83% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.92 vs. LH: 1.02 )
Ranked among companies with meaningful Price/Projected FCF only.
LH' s 10-Year Price/Projected FCF Range
Min: 0.68  Med: 1.03 Max: 6.11
Current: 1.02
0.68
6.11
Price/DCF (Earnings Based) 1.79
LH's Price/DCF (Earnings Based) is ranked higher than
71% of the 14 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.23 vs. LH: 1.79 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.98
LH's Price/Median PS Value is ranked higher than
64% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. LH: 0.98 )
Ranked among companies with meaningful Price/Median PS Value only.
LH' s 10-Year Price/Median PS Value Range
Min: 0.07  Med: 0.94 Max: 1.73
Current: 0.98
0.07
1.73
Price/Peter Lynch Fair Value 5.07
LH's Price/Peter Lynch Fair Value is ranked lower than
86% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. LH: 5.07 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
LH' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.86  Med: 1.42 Max: 5.23
Current: 5.07
0.86
5.23
Earnings Yield (Greenblatt) (%) 4.59
LH's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. LH: 4.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LH' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4.5  Med: 8.30 Max: 11.3
Current: 4.59
4.5
11.3
Forward Rate of Return (Yacktman) (%) 10.26
LH's Forward Rate of Return (Yacktman) (%) is ranked lower than
52% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.17 vs. LH: 10.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LH' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 9.1  Med: 19.00 Max: 23.6
Current: 10.26
9.1
23.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ALR, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:LAB.Germany,
Laboratory Corp of America Hldgs, founded in 1971, is an independent clinical laboratory company in the United States. Since the Company's founding, it has grown into a national network of 39 primary laboratories and over 1,750 patient service centers along with a network of branches and STAT laboratories (which are laboratories that have the ability to perform certain routine tests quickly and report the results to the physician immediately). Through its national network of laboratories, the Company offers a broad range of clinical laboratory tests that are used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. In addition, the Company has developed testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials. Laboratory tests and procedures are used generally by hospitals, physicians and other health care providers and commercial clients to assist in the diagnosis, evaluation, detection, therapy selection, monitoring and treatment of diseases and other medical conditions through the examination of substances in the blood, tissues and other specimens. The Company believes that it competes favorably with its principal competitors in each of these areas and is currently implementing strategies designed to improve its competitive position. The Company's strategic plan continues to focus on three critical priorities: scientific differentiation, managed care, and customer service. The Company offers its services through a sales force focused on serving the specific needs of customers in different market segments. These market segments generally include Primary Care, Obstetrics-Gynecology, Specialty Medicine (e.g., Infectious Disease, Endocrinology, Gastroenterology and Rheumatology), Oncology and Hospitals. The Company is subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety and laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials.
» More Articles for LH

Headlines

Articles On GuruFocus.com
John Hussman's Top Five New Buys in the First Quarter May 12 2015 
John Hussman Increases Portfolio in 1Q2015 May 04 2015 
Laboratory Corporation of America Holdings Q4 Earnings Beat Market Expectations Feb 24 2015 
Westport Buys Apparel Retailer Express During Q4 Feb 11 2015 
Investment Ideas from Guy Spier - Part 2 Jan 07 2015 
The Top Five Guru-Held Mid-Cap Stocks of Q2 Sep 04 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
Tom Gayner’s Top 5 New Portfolio Picks Aug 11 2014 
Top Five Guru-Owned Mid Cap Stocks Jun 18 2014 
John Rogers Comments on Laboratory Corp. of America Holdings May 07 2014 

More From Other Websites
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Jul 01 2015
8:47 am Laboratory Corp announces the conversion ability of its zero coupon convertible subordinated... Jul 01 2015
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 Jul 01 2015
LabCorp to PRL employees: You're safe, for now Jun 16 2015
KeyBanc Starts Lab Corp Of America At Overweight, But Indebtedness Is A Concern Jun 16 2015
Analysts' Actions -- AIG, Standard Pacific, Twitter and More Jun 16 2015
Coverage initiated on Laboratory Corp by KeyBanc Capital Mkts Jun 16 2015
Shh! Physicians Reference Lab gets new owner Jun 11 2015
Merger Boom Spawns a CFO Surplus Jun 09 2015
Barron's Recap: GOP Contenders, Corning's Latest Magic & Apple Watch Called 'Not So Smart' Jun 07 2015
LabCorp's shares could rise 20 pct in the next year -Barron's Jun 07 2015
Bio-Reference Laboratories, Inc.: Leads amongst peers with strong fundamentals Jun 06 2015
LabCorp's Results Could Lift Shares 20% Jun 05 2015
LabCorp Expands Access to LabCorp AccuDraw® to Support Better Patient Care Jun 04 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Jun 04 2015
LabCorp Expands Access to LabCorp AccuDraw® to Support Better Patient Care Jun 04 2015
Omicia Wins UK's 100,000 Genomes Project as Clinical Interpretation Provider Jun 04 2015
LabCorp is Scheduled to Present at the Goldman Sachs 36th Annual Global Healthcare Conference Jun 02 2015
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Jun 02 2015
LabCorp is Scheduled to Present at the Goldman Sachs 36th Annual Global Healthcare Conference Jun 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK